keyword
MENU ▼
Read by QxMD icon Read
search

"peptide receptor radionuclide therapy"

keyword
https://www.readbyqxmd.com/read/27928785/-interpretation-of-the-latest-guidelines-in-the-treatment-of-gastrointestinal-neuroendocrine-neoplasms
#1
Luohai Chen, Jie Chen, Zhiwei Zhou
Neuroendocrine neoplasms(NEN) is a rare group of tumors with gastrointestinal tract as one of the most common primary locations. The most commonly used guidelines are proposed by European Neuroendocrine Tumor Society (ENETS) and National Comprehensive Cancer Network(NCCN) respectively, while the management of gastrointestinal NEN is generally identical in these two guidelines. Surgery is still the sole curative method which should be considered as the first choice of locoregional NEN. Otherwise, 40% to 50% of patients manifests metastatic disease when diagnosed...
November 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27922860/the-impact-of-radiological-response-to-peptide-receptor-radionuclide-therapy-on-overall-survival-in-patients-with-metastatic-midgut-neuroendocrine-tumors
#2
Mehmet Yalchin, Amelia Oliveira, Eleni Theocharidou, Deborah Pencharz, Shaunak Navalkissoor, Ann-Marie Quigley, Martin Walker, Martyn Caplin, Christos Toumpanakis
PURPOSE OF THE REPORT: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced neuroendocrine tumors (NET); however, long-term survival data are scarce. The aim of this study is to determine long-term survival in patients with metastatic midgut NET, according to response to PRRT. PATIENTS AND METHODS: One hundred thirty-three consecutive patients with progressive metastatic midgut NET underwent PRRT. Response at 1 year post PRRT was classified as partial response, stable disease, disease progression, or death...
December 3, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27906859/recent-advances-in-nuclear-medicine-in-endocrine-oncology
#3
Markus Luster, Andreas Pfestroff, Frederik A Verburg
PURPOSE OF REVIEW: The purpose is to review recent advances concerning the role of nuclear medicine in endocrine oncology. RECENT FINDINGS: For I therapy of thyroid cancer a thyrotropin (TSH) more than 30 mU/l has for many years been deemed a condition sine qua non. However, new data show that patients with lower TSH levels at the time of ablation have the same rate of successful ablation as those with TSH more than 30 mU/l.I-124 combined integrated positron emission tomography and computed X-ray tomography was shown to be highly accurate in predicting findings on posttherapy radioiodine scanning and was shown to have a high prognostic power...
January 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27905851/peptide-receptor-radionuclide-therapy-for-sarcoidosis
#4
Constantin Lapa, Götz Ulrich Grigoleit, Heribert Hänscheid, Erdwine Klinker, Pius Jung, Ken Herrmann, Andreas Schirbel, Markus Böck, Andreas K Buck, Theo Pelzer
No abstract text is available yet for this article.
December 1, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27885372/treatment-planning-in-prrt-based-on-simulated-pet-data-and-a-pbpk-model-determination-of-accuracy-using-a-pet-noise-model
#5
Deni Hardiansyah, Wei Guo, Ali Asgar Attarwala, Peter Kletting, Felix M Mottaghy, Gerhard Glatting
AIM: To investigate the accuracy of treatment planning in peptide-receptor radionuclide therapy (PRRT) based on simulated PET data (using a PET noise model) and a physiologically based pharmacokinetic (PBPK) model. METHODS: The parameters of a PBPK model were fitted to the biokinetic data of 15 patients. True mathematical phantoms of patients (MPPs) were the PBPK model with the fitted parameters. PET measurements after bolus injection of 150 MBq (68)Ga-DOTATATE were simulated for the true MPPs...
November 25, 2016: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27875420/molecular-imaging-in-neuroendocrine-tumors-recent-advances-controversies-unresolved-issues-and-roles-in-management
#6
Tetsuhide Ito, Robert T Jensen
PURPOSE OF REVIEW: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. RECENT FINDINGS: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA...
November 21, 2016: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/27873240/improved-safety-and-efficacy-of-213-bi-dotatate-targeted-alpha-therapy-of-somatostatin-receptor-expressing-neuroendocrine-tumors-in-mice-pre-treated-with-l-lysine
#7
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, Monique Nysus, Mehran Makvandi, Erik de Blois, Wouter A Breeman, Robert W Atcher, Marion de Jong, Jeffrey P Norenberg
BACKGROUND: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with (177)Lu-DOTATATE or (90)Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the proximal tubules, thereby enabling higher radioactivity to be safely administered...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27853048/does-combination-of-cold-and-hot-somatostatin-analogs-prolong-survival-of-patients-with-neuroendocrine-neoplasms
#8
Anna Sowa-Staszczak, Agnieszka Stefanska, Pawel Chrapczynski, Malgorzata Trofimiuk-Müldner, Miroslaw Szura, Alicja Hubalewska-Dydejczyk
A number of detected neuroendocrine neoplasms (NENs) has been on the increase due to our awareness of the NENs risk and the development of different imaging techniques. Therapy of NENs involves surgery, chemotherapy, "cold" somatostatin analogs (SSA), peptide receptor radionuclide therapy (PRRT) and kinase inhibitors in pancreatic NENs. The aim of this study is to assess the efficacy of SSA in combination with "hot" somatostatin analogs, and the survival rate of our patients with advanced NENs. Seventy nine patients with metastatic NEN and positive somatostatin receptor scintigraphy (SRS) were enrolled in the study...
November 17, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27811124/molecular-imaging-of-gastroenteropancreatic-neuroendocrine-tumors-current-status-and-future-directions
#9
REVIEW
Christophe M Deroose, Elif Hindié, Electron Kebebew, Bernard Goichot, Karel Pacak, David Taïeb, Alessio Imperiale
Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine has earned a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs). GEP NETs are diagnosed fortuitously or on the basis of symptoms or hormonal syndrome. The functional tumor characteristics shown by radionuclide imaging allow for more accurate staging and treatment selection. Tumor grade helps determine which tracer should be selected. In the past, (111)In-pentetreotide has been successful in well-differentiated (G1 and G2) tumors...
December 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27789751/nuclear-imaging-in-metastatic-paraganglioma
#10
REVIEW
Rohit Kedia, Neil Hansen, Whitney Goldner
Paragangliomas associated with mutations of the SDHD gene can occasionally result in distant metastasis. Diagnosis can be difficult, and nuclear imaging is used to evaluate the case further. Not all tumors are alike; nuclear avidity may differ. We present a case in which metastatic paraganglioma caused by mutations of the SDHD gene was negative on (123)I-metaiodobenzylguanidine scintigraphy and positive on (111)In-labeled octreotide scintigraphy. This situation presents an opportunity for a novel therapeutic approach toward metastatic paraganglioma using targeted peptide receptor radionuclide therapy...
December 2016: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/27759712/peptide-receptor-radionuclide-therapy-outcomes-in-a-north-american-cohort-with-metastatic-well-differentiated-neuroendocrine-tumors
#11
Nancy Sharma, Boris G Naraev, Eric G Engelman, M Bridget Zimmerman, David L Bushnell, Thomas M OʼDorisio, M Sue OʼDorisio, Yusuf Menda, Jan Müller-Brand, James R Howe, Thorvardur R Halfdanarson
OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men...
October 18, 2016: Pancreas
https://www.readbyqxmd.com/read/27749410/successful-repeated-peptide-receptor-radionuclide-therapies-in-renal-neuroendocrine-tumor-with-osseous-metastasis
#12
Anna Yordanova, Karin Mayer, Markus Essler, Hojjat Ahmadzadehfar
Renal neuroendocrine tumor (NET) is an extremely rarely occurring disease. The sporadic reports in the literature are mostly case reports, or less commonly small studies. In cases of metastatic disease from renal NET, there are no established therapies. We are reporting our experience with a patient with extensive osseous infiltration of a renal NET, who was successfully treated with peptide receptor radionuclide therapy (PRRT) using Lu-DOTATATE. In a period of 10 years, the patient underwent in total 12 cycles of PRRT with a cumulative dose of 81 GBq...
December 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27743210/predictive-value-of-asphericity-in-pretherapeutic-111-in-dtpa-octreotide-spect-ct-for-response-to-peptide-receptor-radionuclide-therapy-with-177-lu-dotatate
#13
Christoph Wetz, I Apostolova, I G Steffen, F Hofheinz, C Furth, D Kupitz, J Ruf, M Venerito, S Klose, Holger Amthauer
PURPOSE: The purpose of this study was to assess the value of the spatial heterogeneity of somatostatin receptor (SSR) volume, quantified as asphericity (ASP), and to predict response to peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). PROCEDURES: From June 2011 to May 2013, patients suffering from GEP-NEN who underwent pretherapeutic [(111)In-DTPA(0)]octreotide scintigraphy (Octreoscan®) prior to [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]DOTATATE)-PRRT were enrolled in this retrospective evaluation...
October 14, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/27713064/aggressive-pituitary-adenomas-the-dark-side-of-the-moon
#14
Stefano M Priola, Felice Esposito, Salvatore Cannavò, Alfredo Conti, Rosaria V Abbritti, Valeria Barresi, Sergio Baldari, Francesco Ferraù, Antonino Germanò, Francesco Tomasello, Filippo F Angileri
BACKGROUND: Although pituitary adenomas are considered benign lesions, a small group may exhibit a clinically aggressive behavior, sometimes independently from the classic markers of aggressiveness, including the Ki67 labeling index and/or p53 expression. METHODS: We selected 7 subjects harboring a pituitary tumor with clinical features of aggressiveness. Patients underwent a full preoperative and postoperative endocrinological and neuroradiological work-up. Two were non-functioning, two PRL-secreting, two ACTH-secreting, and one a GH-secreting adenoma...
October 3, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27705948/survival-prediction-in-patients-undergoing-radionuclide-therapy-based-on-intratumoral-somatostatin-receptor-heterogeneity
#15
Rudolf A Werner, Constantin Lapa, Harun Ilhan, Takahiro Higuchi, Andreas K Buck, Sebastian Lehner, Peter Bartenstein, Frank Bengel, Imke Schatka, Dirk O Muegge, László Papp, Norbert Zsótér, Tobias Große-Ophoff, Markus Essler, Ralph A Bundschuh
The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the prognostic value of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 patients with SSTR-expressing tumors were analyzed obtaining SSTR-PET/CT before PRRT (1-6 cycles, 177Lu somatostatin analog)...
October 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27688470/nampt-inhibitor-gmx1778-enhances-the-efficacy-of-177lu-dotatate-treatment-of-neuroendocrine-tumors
#16
Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson, Viktor Johanson
: Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. AIMS: To evaluate the potential radiosensitizing effects of NAMPT inhibition on (177)Lu-DOTATATE treatment in a NET model. METHODS: Nude mice xenografted with the human NET cell line GOT1 were treated with semi-efficient doses of (177)Lu-DOTATATE (7,5 MBq, i...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27678267/high-clinical-and-morphologic-response-using-90-y-dota-octreotate-sequenced-with-177-lu-dota-octreotate-induction-peptide-receptor-chemoradionuclide-therapy-prcrt-for-bulky-neuroendocrine-tumours
#17
Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks
PURPOSE: Bulky disease is an adverse prognostic factor for (177)Lu-DOTA-octreotate ((177)Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT). (90)Y-DOTA-octreotate ((90)Y-DOTATATE) has theoretical advantages in this setting but may less effectively treat co-existent smaller deposits and have higher toxicity than (177)Lu-DOTATATE. The aim of this study was to assess the efficacy and safety of using these agents sequentially. METHODS: We reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of (90)Y-DOTATATE followed by 2-3 cycles of (177)Lu-DOTATATE, with treatment empirically adapted to disease size and burden in individual patients...
September 27, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27659006/influence-of-voxel-s-factors-on-three-dimensional-internal-dosimetry-calculations
#18
Salvatore Berenato, Ernesto Amato, Alexander Fischer, Sergio Baldari
Internal dosimetry is a fundamental instrument for the personalization of nuclear medicine therapies, to maximize the therapeutic effect while minimizing the radiation burden to other organs. Three-dimensional (3D) dosimetry can quantify the impact of heterogeneous radiopharmaceutical distributions in organs, lesions and tissues. We analysed the influence of radionuclide voxel S factors in 3D dosimetry of (111)In, (177)Lu and (90)Y, the most used radionuclides in Peptide Receptor Radionuclide Therapy (PRRT)...
September 19, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27649723/systemic-therapies-in-neuroendocrine-tumors-and-novel-approaches-towards-personalised-medicine
#19
Marianne Pavel, Christine Sers
Neuroendocrine tumors (NET) are a group of heterogenous neoplasms. Evidence-based treatment options for antiproliferative therapy include somatostatin analogs, the mTOR inhibitor everolimus, the multiple tyrosine kinase inhibitor sunitinib and peptide receptor radionuclide therapy with 177-Lu-octreotate. In the absence of definite predictive markers therapeutic decision making follows clinical and pathological criteria. Since objective reponse rates with targeted drugs are rather low, and response duration is limited in most patients, numerous combination therapies targeting multiple pathways have been explored in the field...
September 20, 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27636009/heterogeneity-of-grade-3-gastroenteropancreatic-neuroendocrine-carcinomas-new-insights-and-treatment-implications
#20
REVIEW
Nicola Fazio, Massimo Milione
Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are currently classified as grade (G) 1, G2 and G3, in accordance with the 2010 WHO classification. G1 and G2 are named neuroendocrine tumors (NETs) whereas G3 neuroendocrine carcinomas (NECs). While advanced G1 and G2 are usually treated with several different therapies, including somatostatin analogs, chemotherapy, interferon, molecular targeted agents, peptide receptor radionuclide therapy (PRRT) and liver-directed treatments, advanced G3 NECs are usually treated with a platinum-etoposide chemotherapy, trusting their clinical homogeneity is similar to that of small cell lung cancer...
August 28, 2016: Cancer Treatment Reviews
keyword
keyword
108898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"